Header Logo

Connection

Yehuda Handelsman to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Cardiovascular Diseases.
Yehuda Handelsman
Connection Strength
8.121
Cardiovascular Diseases
  1. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):161-170.
    View in: PubMed
    Score: 0.722
  2. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2023 02; 37(2):108389.
    View in: PubMed
    Score: 0.697
  3. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.647
  4. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.596
  5. Paradigm shift in the management of DM & CVD-preventing the next CV event. J Diabetes. 2020 Sep; 12(9):630-632.
    View in: PubMed
    Score: 0.593
  6. Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. J Diabetes. 2019 Apr; 11(4):258-260.
    View in: PubMed
    Score: 0.528
  7. World congress on insulin resistance, diabetes and cardiovascular disease. J Diabetes. 2018 Oct; 10(10):776-777.
    View in: PubMed
    Score: 0.510
  8. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc. 2018 06 22; 7(13).
    View in: PubMed
    Score: 0.509
  9. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
    View in: PubMed
    Score: 0.469
  10. Diabetes and hypertension: a comprehensive report on management and the prevention of cardiovascular and renal complications. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):221-3.
    View in: PubMed
    Score: 0.308
  11. The Avandia debate: an unhappy conclusion. J Diabetes. 2010 Dec; 2(4):221-2.
    View in: PubMed
    Score: 0.301
  12. Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
    View in: PubMed
    Score: 0.210
  13. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
    View in: PubMed
    Score: 0.186
  14. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Expert Rev Cardiovasc Ther. 2022 Aug; 20(8):609-625.
    View in: PubMed
    Score: 0.169
  15. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Vasc Health Risk Manag. 2020; 16:403-418.
    View in: PubMed
    Score: 0.149
  16. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.138
  17. Gerald Reaven: A man for our times. Diab Vasc Dis Res. 2019 03; 16(2):113-115.
    View in: PubMed
    Score: 0.133
  18. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399.
    View in: PubMed
    Score: 0.133
  19. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S42-S52.
    View in: PubMed
    Score: 0.129
  20. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
    View in: PubMed
    Score: 0.121
  21. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.117
  22. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.116
  23. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocr Pract. 2017 Jan; 23(1):100-112.
    View in: PubMed
    Score: 0.114
  24. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol. 2015 Sep 01; 66(9):1050-67.
    View in: PubMed
    Score: 0.105
  25. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS. Endocr Pract. 2015 Sep; 21(9):1054-65.
    View in: PubMed
    Score: 0.104
  26. Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
    View in: PubMed
    Score: 0.081
  27. Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60.
    View in: PubMed
    Score: 0.081
  28. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
    View in: PubMed
    Score: 0.072
  29. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
    View in: PubMed
    Score: 0.026
  30. Practical perspectives on the management of overweight and obesity. Am J Manag Care. 2014 Mar; 20(3 Suppl):S64-75.
    View in: PubMed
    Score: 0.024
  31. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.022
  32. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.